A. Rabow

发表

Mining the NCI screening database: explorations of agents involved in cell cycle regulation.

D. Covell, A. Monks, R. Shoemaker, 2003, Progress in cell cycle research.

Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat.

Peter D Smith, A. Rabow, R. A. Norman, 2016, ACS medicinal chemistry letters.

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.

A. Rabow, D. M. Andrews, G. Walker, 2015, Journal of medicinal chemistry.

Molecular classification of cancer: unsupervised self-organizing map analysis of gene expression microarray data.

D. Covell, A. Wallqvist, A. Rabow, 2003, Molecular cancer therapeutics.

Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology.

Anders Wallqvist, E. Sausville, D. Covell, 2002, Molecular cancer therapeutics.

Application of high-throughput, molecular-targeted screening to anticancer drug discovery.

D. Scudiero, E. Sausville, D. Covell, 2002, Current topics in medicinal chemistry.

Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).

C. A. Roberts, A. Rabow, M. Waring, 2016, Journal of medicinal chemistry.

Discovery of a Potent and Selective ATAD2 Bromodomain Inhibitor with Antiproliferative Activity in Breast Cancer Models.

Nichola L. Davies, A. Rabow, S. Guichard, 2022, Journal of medicinal chemistry.

Running title : Pharmacology of SERD inhibitor in breast cancer models

Graham, A. Rabow, R. A. Norman, 2016 .

Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer.

A. Rabow, D. M. Andrews, G. Walker, 2011, Bioorganic & medicinal chemistry letters.

Abstract 3848: Preclinical profile of AZD3514: A small molecule-targeting androgen receptor function with a novel mechanism of action and the potential to treat castration-resistant prostate cancer

A. Rabow, C. Robson, G. Walker, 2012 .

AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo

Rhys D O Jones, A. Rabow, S. Barry, 2013, Molecular Cancer Therapeutics.

Small Molecule Therapeutics AZD 3514 : A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo

Rhys D O Jones, A. Rabow, S. Barry, 2013 .

Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.

Rhys D O Jones, A. Rabow, G. Walker, 2013, Bioorganic & medicinal chemistry letters.

Linking tumor cell cytotoxicity to mechanism of drug action: An integrated analysis of gene expression, small‐molecule screening and structural databases

Ruili Huang, Narmada Thanki, Anders Wallqvist, 2005, Proteins.

Data mining of NCI's anticancer screening database reveals mitochondrial complex I inhibitors cytotoxic to leukemia cell lines.

D. Covell, R. Shoemaker, A. Rabow, 2007, Biochemical pharmacology.

Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data

Anders Wallqvist, Alfred A. Rabow, Robert H. Shoemaker, 2003, Bioinform..

Potent and selective bivalent inhibitors of BET bromodomains.

A. Dulak, A. Rabow, M. Waring, 2016, Nature chemical biology.

A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs)

A. Rabow, G. Walker, R. Callis, 2015, Journal of biomolecular screening.

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

G. Mills, A. Dulak, A. Rabow, 2016, Molecular Cancer Therapeutics.

Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities.

E. Sausville, D. Covell, R. Shoemaker, 2002, Journal of medicinal chemistry.

Improved genetic algorithm for the protein folding problem by use of a Cartesian combination operator

H A Scheraga, A A Rabow, H. Scheraga, 1996, Protein science : a publication of the Protein Society.

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

A. Rabow, G. Walker, R. A. Norman, 2016, Cancer research.

Abstract DDT01-03: Discovery and pre-clinical pharmacology of AZD9496: An oral, selective estrogen receptor down-regulator (SERD)

A. Rabow, D. M. Andrews, G. Walker, 2015 .

Enantiomeric pairs reveal that key medicinal chemistry parameters vary more than simple physical property based models can explain

Alfred A. Rabow, Andrew G. Leach, A. Rabow, 2012 .

Molecular Classification of Cancer : Unsupervised Self-Organizing Map Analysis of Gene Expression Microarray Data 1

D. Covell, A. Wallqvist, A. Rabow, 2003 .

An improved model for fragment-based lead generation at AstraZeneca.

Qing Cao, Fredrik Edfeldt, Nathan Fuller, 2016, Drug discovery today.